GlassScriptPhysician profile
Victoria Baskin
NPI 1801831409
$4,101.85
in general payments reported to CMS, 2019-2025
23 companies · $881 in 2025
The $881 reported for 2025 was more than what 84% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $101 · 2020: $95.17 · 2021: $407 · 2022: $782 · 2023: $993 · 2024: $842 · 2025: $881.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,606 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,605.51 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $957.76 | 2021-2024 | Vraylar, Mavyret |
| Neurocrine Biosciences, INC. | $599.69 | 2023-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $403.08 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $272.90 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Supernus Pharmaceuticals, INC. | $236.25 | 2022-2024 | Qelbree, Qelbree |
| Corium, LLC | $230.53 | 2021-2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $221.25 | 2021-2022 | |
| Almatica Pharma LLC | $208.17 | 2022-2025 | Loreev Xr, Sertraline Hcl |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $190.57 | 2022-2025 | Caplyta |
| Allergan, INC. | $137.50 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $113.48 | 2020-2024 | Jornay Pm |
| Lundbeck LLC | $83.62 | 2024 | Rexulti |
| Viiv Healthcare Company | $83.11 | 2021-2023 | Rukobia, Cabenuva |
| Indivior INC. | $68.12 | 2021-2024 | Sublocade |
| Collegium Pharmaceutical, INC. | $63.51 | 2025 | Jornay Pm |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $57.85 | 2023-2024 | Vivitrol, Vivitrol |
| Sunovion Pharmaceuticals INC. | $37.95 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $34.99 | 2024 | Hetlioz, Fanapt |
| Theratechnologies INC. | $25.60 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $24.67 | 2025 | Cobenfy |
| Tris Pharma INC | $20.54 | 2025 | Quillivant |
| Shire North American Group INC | $16.12 | 2019 | |
| Hologic Sales and Service, LLC | $14.59 | 2025 | Aptima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victoria Baskin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.